Gensight Biologics S.a annual total debt
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Total Debt Growth & History (SIGHT)
Gensight Biologics S.a's total debt was €12.9M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €12.9M | €5.4M | +72.89% |
| 2024 | 2024-12-31 | €7.4M | −€1.9M | −19.97% |
| 2023 | 2023-12-31 | €9.3M | €6.2M | +200.00% |
| 2022 | 2022-12-31 | €3.1M | €852,000 | +37.92% |
| 2021 | 2021-12-31 | €2.2M | −€358,000 | −13.74% |
| 2020 | 2020-12-31 | €2.6M | — | — |
Gensight Biologics S.a quarterly total debt
Q4.24
Q4.25
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | €12.9M | −€1.6M | −10.75% |
| Q4 2024 | 2024-12-31 | €14.4M | — | — |
Gensight Biologics S.a total debt trends
Over the last five fiscal years, Gensight Biologics S.a's total debt increased from €2.6M to €12.9M, a change of €10.3M. The latest reported quarter, Q4 2025, shows €12.9M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from official filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...